Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 90 of 106 results for rituximab

  1. Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular or marginal zone lymphoma after 1 or more anti-CD20 treatments ID6413

    Awaiting development [GID-TA11488] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Lymphoma (non Hodgkin's) - bendamustine (with rituximab) [ID434]

    Discontinued [GID-TAG278]

    Technology appraisal guidance
    Discontinued

  3. Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]

    Discontinued [GID-TAG321]

    Technology appraisal guidance
    Discontinued

  4. Idelalisib with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia [ID839]

    Discontinued [GID-TA10109]

    Technology appraisal guidance
    Discontinued

  5. Ofatumumab (Arzerra) in combination with chemotherapy for follicular lymphoma; second line - refractory to rituximab [ID1487]

    Discontinued [GID-TA10437]

    Technology appraisal guidance
    Discontinued

  6. Rituximab for aggressive non-Hodgkin's lymphoma (TA65)

    After consultation the guidance has been withdrawn because it is no longer relevant to clinical practice. Rituximab is now routinely used outside its licensed indication. See NICE’s guideline on non-Hodgkin’s lymphoma.

    Technology appraisal guidance
    Published
    24 September 2003

  7. Rituximab for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs [ID333]

    Discontinued [GID-TAG418]

    Technology appraisal guidance
    Discontinued

  8. Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]

    Discontinued [GID-TA10332]

    Technology appraisal guidance
    Discontinued

  9. Factors predicting outcomes for people with high-grade transformation of follicular lymphoma:- In people with high-grade transformation of follicular lymphoma, which biological and clinical factors predict good outcomes with immunochemotherapy alone?

    Any explanatory notes(if applicable) Why this is important:- Before rituximab, it was accepted that high-grade transformation of...

    Research recommendation
    Published
    25 August 2016

  10. Idelalisib for treating refractory follicular lymphoma (TA604)

    Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults.

    Technology appraisal guidance
    Published
    2 October 2019
    View recommendations

    Sections for TA604

  11. Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)

    Evidence-based recommendations on nintedanib for treating progressive fibrosing interstitial lung diseases in adults.

    Technology appraisal guidance
    Published
    17 November 2021
    View recommendations

    Sections for TA747

  12. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (TA872)

    Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma in adults after 2 or more systemic therapies.

    Technology appraisal guidance
    Published
    28 February 2023

    Sections for TA872

  13. Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma [ID1444]

    In development [GID-TA10477] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)

    Evidence-based recommendations on voclosporin (Lupkynis) with mycophenolate mofetil for treating lupus nephritis in adults.

    Technology appraisal guidance
    Published
    3 May 2023
    View recommendations

    Sections for TA882

  15. Rituximab for the treatment of follicular lymphoma (TA110)

    This guidance has been updated and replaced by NICE technology appraisal guidance 243.

    Technology appraisal guidance
    Published
    27 September 2006